You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

268 Results
Guidelines and Advice
Status: In-Review
ID: RR 21-5
Version: n/a
Jan 2019
Blog post
Anyone who has lived with a diagnosis of cancer or has supported a loved one through treatment knows the toll that the illness can carry. Travelling...
Apr 2019
Document
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Lymphocytic (CLL)
Intent: Palliative
Funding:
Exceptional Access Program
    venetoclax - In Combination with Rituximab - Relapsed Chronic Lymphocytic Leukemia, based on criteria
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - In Combination with Venetoclax - Relapsed Chronic Lymphocytic Leukemia
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - In Combination with Venetoclax - Relapsed Chronic Lymphocytic Leukemia
Sep 2025
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Funding:
New Drug Funding Program
    Bortezomib - In Combination with Selinexor and Dexamethasone for Previously Treated Multiple Myeloma
ODB - General Benefit
    dexamethasone
Exceptional Access Program
    selinexor - In combination with bortezomib and dexamethasone for relapsed or refractory multiple myeloma
Nov 2024
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Myeloid (CML)
Intent: Palliative
Nov 2024
Document
Document

Pages